Čepulytė Rūta, Žučenka Andrius, Pečeliūnas Valdas
Vilnius University Hospital Santaros Klinikos, Center of Hematology, Oncology and Transfusion Medicine, Santariškių 2, Vilnius 08661, Lithuania.
Vilnius University Faculty of Medicine, Institute of Clinical Medicine, Clinic of Internal Diseases, Family Medicine and Oncology, Santariškių 2, Vilnius 08661, Lithuania.
Case Rep Hematol. 2020 Oct 15;2020:8894031. doi: 10.1155/2020/8894031. eCollection 2020.
Multiple myeloma (MM) is an incurable plasma cell neoplasia characterized by relapsed and/or refractory (R/R) disease course, which poses a major therapeutic challenge. New therapies, including BRAF V600E mutation targeting, may become a new treatment option for R/R MM. In combination with mitogen-activated protein kinase inhibitors (MEKi), BRAF inhibitors (BRAFi) could provide better tailored clinical management, although experience in this field is lacking. To this date, there is only one case describing R/R MM treatment with BRAFi vemurafenib and MEKi cobimetinib. This is the first case presenting a R/R MM patient treated with BRAFi dabrafenib and MEKi trametinib.
多发性骨髓瘤（MM）是一种无法治愈的浆细胞肿瘤，其特征为疾病复发和/或难治（R/R），这构成了重大的治疗挑战。包括靶向BRAF V600E突变在内的新疗法可能成为R/R MM的新治疗选择。与丝裂原活化蛋白激酶抑制剂（MEKi）联合使用时，BRAF抑制剂（BRAFi）可以提供更精准的临床管理，尽管该领域缺乏相关经验。迄今为止，仅有1例关于使用BRAFi维莫非尼和MEKi考比替尼治疗R/R MM的病例报道。本文首次报道了1例使用BRAFi达拉非尼和MEKi曲美替尼治疗的R/R MM患者。
